DWS Global Macro Fund

	Shares	Value (\$)
Common Stocks 38.6%		
Canada 0.4%		
Nutrien Ltd. (Cost \$921,970)	13,988	722,200
Denmark 0.8%		
Novo Nordisk A/S "B" (Cost \$2,073,977)	15,336	1,298,107
France 7.3%		
AXA SA	104,849	3,971,621
BNP Paribas SA	17,490	1,188,338
Bureau Veritas SA	15,969	499,162
Capgemini SE	4,144	751,245
EssilorLuxottica SA	3,646	1,001,255
LVMH Moet Hennessy Louis Vuitton SE	1,139	824,931
Orange SA	32,153	346,361
Sanofi SA	12,333	1,338,574
Schneider Electric SE	5,693	1,438,743
Veolia Environnement SA	30,995	879,770
(Cost \$9,436,377)		12,240,000
Germany 5.7%		
Allianz SE (Registered)	9,774	3,183,530
Deutsche Telekom AG (Registered)	69,460	2,335,404
E.ON SE	190,030	2,242,567
Vonovia SE	60,014	1,833,329
(Cost \$6,293,401)	_	9,594,830
Ireland 1.7%		
Medtronic PLC (a)	22,022	2,000,038
TE Connectivity PLC (a)	5,835	863,405
(Cost \$2,729,968)	_	2,863,443
T. 1. 0.70/		
Italy 0.5%	100.001	0-4
Enel SpA (Cost \$907,951)	120,204	852,617
Japan 1.5%		
Daikin Industries Ltd.	6,800	801,205
Keyence Corp.	2,000	861,530
Takeda Pharmaceutical Co., Ltd.	34,200	923,885
(Cost \$3,154,663)		2,586,620
Korea 0.8%		
Samsung Electronics Co., Ltd. (Cost \$2,026,562)	38,669	1,384,739
Netherlands 2.1%		
ASML Holding NV	579	428,477

NG Groep NV		70,304	1,166,391
Koninklijke Ahold Delhaize NV		55,568	1,969,856
Cost \$2,641,250)			3,564,724
Switzerland 1.8%			
Novartis AG (Registered)		6,262	655,998
Roche Holding AG (Genusschein)		7,825	2,445,316
Cost \$2,438,704)		_	3,101,314
Taiwan 0.3%			
Faiwan Semiconductor Manufacturing Co., Ltd. (b) (Cost \$385,079)		14,000	455,324
United States 15.7%			
Alphabet, Inc. "A"		27,251	5,559,749
amazon.com, Inc.*		9,469	2,250,592
aton Corp. PLC		3,402	1,110,549
ubbell, Inc.		2,024	856,172
inde PLC		3,843	1,714,439
astercard, Inc. "A"		1,540	855,362
Ierck & Co., Inc.		14,801	1,462,635
leta Platforms, Inc. "A"		2,219	1,529,290
icrosoft Corp.		10,031	4,163,467
yPal Holdings, Inc.*		14,801	1,311,073
izer, Inc.		65,712	1,742,682
erviceNow, Inc.*		501	510,208
per Technologies, Inc.*		18,820	1,258,117
nion Pacific Corp.		4,567	1,131,657
·			
ısa, Inc. "A"		3,136	1,071,885
		3,136	
isa, Inc. "A" Cost \$17,354,402) otal Common Stocks (Cost \$50,364,304)		3,136	1,071,885 26,527,877 65,191,795
Cost \$17,354,402)		3,136 _	26,527,877
Cost \$17,354,402)	_ <u>A</u> n		26,527,877
Cost \$17,354,402)	<u>Ar</u>	Principal	26,527,877 65,191,795
Cost \$17,354,402) otal Common Stocks (Cost \$50,364,304) Bonds 41.0%	<u>Ar</u>	Principal	26,527,877 65,191,795
Cost \$17,354,402) otal Common Stocks (Cost \$50,364,304) Bonds 41.0% etherlands 0.9%	<u>Ar</u>	Principal	26,527,877 65,191,795
Cost \$17,354,402) Otal Common Stocks (Cost \$50,364,304) Bonds 41.0% etherlands 0.9% IG Groep NV, 3.95%, 3/29/2027	<u>Ar</u> EUR	Principal nount (\$) (c)	26,527,877 65,191,795 Value (\$)
Bonds 41.0% etherlands 0.9% IG Groep NV, 3.95%, 3/29/2027 Eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025		Principal nount (\$) (c)	26,527,877 65,191,795 Value (\$)
Cost \$17,354,402) otal Common Stocks (Cost \$50,364,304) Bonds 41.0% Getherlands 0.9% NG Groep NV, 3.95%, 3/29/2027 eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Cost \$1,420,620)		Principal nount (\$) (c)	26,527,877 65,191,795 Value (\$) 639,468 829,920
Cost \$17,354,402) ptal Common Stocks (Cost \$50,364,304) Bonds 41.0% etherlands 0.9% NG Groep NV, 3.95%, 3/29/2027 eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Cost \$1,420,620) urkey 0.4%		Principal nount (\$) (c)	26,527,877 65,191,795 Value (\$) 639,468 829,920
Bonds 41.0% Bonds 41.0% etherlands 0.9% IG Groep NV, 3.95%, 3/29/2027 Eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Cost \$1,420,620) Burkey 0.4% Equilibric of Turkey:		Principal nount (\$) (c)	26,527,877 65,191,795 Value (\$) 639,468 829,920
Cost \$17,354,402) Detal Common Stocks (Cost \$50,364,304) Bonds 41.0% etherlands 0.9% NG Groep NV, 3.95%, 3/29/2027 Eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Cost \$1,420,620) Burkey 0.4% epublic of Turkey: 3.25%, 6/14/2025	EUR	Principal nount (\$) (c) 650,000 800,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388
Bonds 41.0% Bonds 41.0% Getherlands 0.9% NG Groep NV, 3.95%, 3/29/2027 Eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Cost \$1,420,620) urkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025	EUR	Principal nount (\$) (c) 650,000 800,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000
Bonds 41.0% Bonds 41.0% Getherlands 0.9% NG Groep NV, 3.95%, 3/29/2027 Eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Cost \$1,420,620) urkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 Cost \$724,333)	EUR	Principal nount (\$) (c) 650,000 800,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388
Cost \$17,354,402) otal Common Stocks (Cost \$50,364,304) Bonds 41.0% Getherlands 0.9% NG Groep NV, 3.95%, 3/29/2027 eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Cost \$1,420,620) furkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 Cost \$724,333) United States 39.7%	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385
Bonds 41.0% Bonds 41.0% etherlands 0.9% G Groep NV, 3.95%, 3/29/2027 va Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 cost \$1,420,620) arkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 cost \$724,333) mited States 39.7% obVie, Inc., 2.95%, 11/21/2026	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385
Bonds 41.0% etherlands 0.9% IG Groep NV, 3.95%, 3/29/2027 IVA Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 IOST \$1,420,620) INTREY 0.4% Equilic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 IOST \$724,333) INITED States 39.7% EDVICE INC., 2.95%, 11/21/2026 Enheuser-Busch InBev Worldwide, Inc., 4.0%, 4/13/2028	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000 170,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385
Bonds 41.0% etherlands 0.9% IG Groep NV, 3.95%, 3/29/2027 Eva Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 Eva States 31,420,620) Burkey 0.4% Expublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 Eva \$724,333) Buited States 39.7% Expublic States 39.	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000 170,000 40,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385 2,921,227 167,191 34,971
Bonds 41.0% etherlands 0.9% IG Groep NV, 3.95%, 3/29/2027 va Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 lost \$1,420,620) arkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 lost \$724,333) nited States 39.7% ebVie, Inc., 2.95%, 11/21/2026 etheuser-Busch InBev Worldwide, Inc., 4.0%, 4/13/2028 ISH DBS Corp., 7.75%, 7/1/2026 ethereral Motors Financial Co., Inc., 2.7%, 8/20/2027	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000 170,000 40,000 1,000,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385 2,921,227 167,191 34,971 948,036
Bonds 41.0% etherlands 0.9% G Groep NV, 3.95%, 3/29/2027 va Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 ost \$1,420,620) nrkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 ost \$724,333) nited States 39.7% ebVie, Inc., 2.95%, 11/21/2026 etheuser-Busch InBev Worldwide, Inc., 4.0%, 4/13/2028 SH DBS Corp., 7.75%, 7/1/2026 etheuser Bunch InBev Worldwide, Inc., 2.7%, 8/20/2027 etheuser Financial Co., Inc., 2.7%, 8/20/2027 etheuser Sinancial Co., Inc., 2.7%, 8/20/2027	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000 170,000 40,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385 2,921,227 167,191 34,971
Bonds 41.0% etherlands 0.9% G Groep NV, 3.95%, 3/29/2027 va Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 lost \$1,420,620) arkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 lost \$724,333) nited States 39.7% eb Vie, Inc., 2.95%, 11/21/2026 cheuser-Busch InBev Worldwide, Inc., 4.0%, 4/13/2028 ISH DBS Corp., 7.75%, 7/1/2026 eneral Motors Financial Co., Inc., 2.7%, 8/20/2027 P. Inc., 3.0%, 6/17/2027 erffix, Inc.:	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000 170,000 40,000 1,000,000 1,100,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385 2,921,227 167,191 34,971 948,036 1,057,290
Bonds 41.0% etherlands 0.9% IG Groep NV, 3.95%, 3/29/2027 va Pharmaceutical Finance Netherlands II BV, 4.5%, 3/1/2025 lost \$1,420,620) arkey 0.4% epublic of Turkey: 3.25%, 6/14/2025 7.375%, 2/5/2025 lost \$724,333) mited States 39.7% obVie, Inc., 2.95%, 11/21/2026 heuser-Busch InBev Worldwide, Inc., 4.0%, 4/13/2028 SH DBS Corp., 7.75%, 7/1/2026	EUR	Principal nount (\$) (c) 650,000 800,000 200,000 500,000 170,000 40,000 1,000,000	26,527,877 65,191,795 Value (\$) 639,468 829,920 1,469,388 207,385 500,000 707,385 2,921,227 167,191 34,971 948,036

U.S. Treasury Bonds:		
3.625%, 2/15/2044	6,700,000	5,669,352
3.75%, 11/15/2043	8,400,000	7,249,922
4.375%, 5/15/2040	6,800,000	6,526,672
4.5%, 5/15/2038	4,900,000	4,842,770
U.S. Treasury Notes:		
2.375%, 5/15/2027	5,460,000	5,242,453
2.375%, 5/15/2029	6,400,000	5,918,750
2.875%, 6/15/2025 (d)	1,900,000	1,889,891
3.5%, 9/15/2025	4,000,000	3,980,375
3.5%, 2/15/2033	6,200,000	5,787,312
3.625%, 5/15/2026	4,200,000	4,168,992
3.75%, 4/15/2026	1,500,000	1,491,563
4.125%, 6/15/2026	6,000,000	5,992,734
VeriSign, Inc., 5.25%, 4/1/2025	300,000	300,030
Verizon Communications, Inc., 2.625%, 8/15/2026	800,000	777,091
Warnermedia Holdings, Inc., 3.755%, 3/15/2027	900,000	871,716
(Cost \$68,299,534)		67,062,690
Total Bonds (Cost \$70,444,487)		69,239,463
	Shares	Value (\$)
Exchange-Traded Funds 12.9%		
Invesco S&P 500 Equal Weight ETF	35,250	6,388,710
iShares EUR High Yield Corp. Bond UCITS ETF	12,663	1,243,060
SPDR Gold MiniShares Trust	255,382	14,168,593
Total Exchange-Traded Funds (Cost \$16,922,141)		21,800,363
Cash Equivalents 5.6%		
DWS Central Cash Management Government Fund, 4.41% (e) (Cost \$9,488,070)	9,488,070	9,488,070
	% of	
	Net Assets	Value (\$)
Total Consolidated Investment Portfolio (Cost \$147,219,002)	98.1	165,719,691
Other Assets and Liabilities, Net	1.9	3,253,692
Net Assets	100.0	168,973,383

 $For information \ on \ the \ Fund's \ policies \ regarding \ the \ valuation \ of \ investments \ and \ other \ significant \ accounting \ policies, \ please \ refer \ to \ the \ Fund's \ most \ recent \ semi-annual \ or \ annual \ financial \ statements.$

A summary of the Fund's transactions with affiliated investments during the period ended January 31, 2025 are as follows:

Value (\$) at 10/31/2024	Purchases Cost (\$)	Sales Proceeds (\$)	Net Realized Gain/ (Loss) (\$)	Net Change in Unrealized Appreciation (Depreciation) (\$)	Income (\$)	Capital Gain Distributions (\$)	Number of Shares at 1/31/2025	Value (\$) at 1/31/2025
	ending Collat nment & Agen		rtfolio "DWS (Government Cash In	stitutional Sh	ares",		
4.28% (e) (f)							
	0 (g)	_	_	_	1,088	_		
Cash Equiva	alents 5.6%							
DWS Centra	l Cash Manage	ement Governme	ent Fund, 4.419	% (e)				
13,009,251	10,158,292	13,679,473	_	_	141,590	_	9,488,070	9,488,070
13,009,251	10,158,292	13,679,473	_	_	142,678	_	9,488,070	9,488,070

^{*} Non-income producing security.

 $⁽a) \quad \textit{Listed on the New York Stock Exchange}.$

- (b) Investment was valued using significant unobservable inputs.
- (c) Principal amount stated in U.S. dollars unless otherwise noted.
- (d) At January 31, 2025, this security has been pledged, in whole or in part, to cover initial margin requirements for open futures contracts.
- (e) Affiliated fund managed by DWS Investment Management Americas, Inc. The rate shown is the annualized seven-day yield at period end.
- (f) Represents cash collateral held in connection with securities lending. Income earned by the Fund is net of borrower rebates.
- (g) Represents the net increase (purchase cost) or decrease (sales proceeds) in the amount invested in cash collateral for the period ended January 31, 2025.

S&P: Standard & Poor's

SPDR: Standard & Poor's Depositary Receipt

At January 31, 2025, open futures contracts purchased were as follows:

		Expiration		Notional	Notional	Unrealized Appreciation/
Futures	Currency	Date	Contracts	Amount (\$)	Value (\$)	(Depreciation) (\$)
10 Year						
U.S. Treasury						
Note	USD	3/20/2025	11	1,208,137	1,197,281	(10,854)
2 Year						
U.S. Treasury						
Note	USD	3/31/2025	5	1,027,395	1,028,125	730
5 Year						
U.S. Treasury						
Note	USD	3/31/2025	45	4,803,861	4,787,578	(16,283)
S&P 500 E-Mini						
Index	USD	3/21/2025	18	5,539,445	5,460,525	(78,920)
Total net unrealize	d depreciation					(105,327)

At January 31, 2025, open futures contracts sold were as follows:

		Expiration		Notional	Notional	Unrealized	
Futures	Currency	Date	Contracts	Amount (\$)	Value (\$)	Depreciation (\$)	
DAX Index	EUR	3/21/2025	12	6,379,048	6,789,578	(410,530)	

At January 31, 2025, the Fund had the following open forward foreign currency contracts:

				Settlement	Unrealized	
Contra	ects to Deliver	1	n Exchange For	Date	Appreciation (\$)	Counterparty
EUR	27,629,427	USD	28,744,882	2/28/2025	45,661	Brown Brothers Harriman & Co.
USD	909,782	NOK	10,314,677	2/28/2025	1,481	Citigroup, Inc.
USD	2,246,700	JPY	347,806,553	2/28/2025	3,058	Toronto-Dominion Bank
Total unrea	alized appreciation	ı			50,200	

				Settlement	Unrealized	
Contra	ects to Deliver]	In Exchange For	Date	Depreciation (\$)	Counterparty
USD	1,689,760	GBP	1,362,691	2/28/2025	(303)	Citigroup, Inc.
USD	958,044	CHF	866,797	2/28/2025	(3,300)	Citigroup, Inc.
Total unrealized depreciation					(3,603)	

Currency Abbreviation(s)

CHF Swiss Franc

 $EUR\ Euro$

GBP British Pound

Investment in Subsidiary

The Fund may seek exposure to gold by investing a portion of its assets in a wholly owned subsidiary organized under the laws of the Cayman Islands (the "Subsidiary"). Among other investments, the Subsidiary may invest in gold ETFs that do not operate as commodity pools, and fixed income instruments. As of January 31, 2025, the Fund held \$1,262,506 in the Subsidiary, representing 0.6% of the Fund's total assets. The Fund's Investment Portfolio has been consolidated and includes the accounts of the Fund and the Subsidiary.

Fair Value Measurements

Various inputs are used in determining the value of the Fund's investments. These inputs are summarized in three broad levels. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds and credit risk). Level 3 includes significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities.

The following is a summary of the inputs used as of January 31, 2025 in valuing the Fund's investments.

Assets	Level 1	Level 2	Level 3	Total
Common Stocks				
Canada	\$ 722,200	\$ _	\$ _	\$ 722,200
Denmark	_	1,298,107	_	1,298,107
France	_	12,240,000	_	12,240,000
Germany	_	9,594,830	_	9,594,830
Ireland	2,863,443	_	_	2,863,443
Italy	_	852,617	_	852,617
Japan	_	2,586,620	_	2,586,620
Korea	_	1,384,739	_	1,384,739
Netherlands	_	3,564,724	_	3,564,724
Switzerland	_	3,101,314	_	3,101,314
Taiwan	_	_	455,324	455,324
United States	26,527,877	_	_	26,527,877
Bonds (a)	· · · · —	69,239,463	_	69,239,463
Exchange-Traded Funds	20,557,303	1,243,060	_	21,800,363
Short-Term Investments	9,488,070	· · · —	_	9,488,070
Derivatives (b)				
Futures Contracts	730	_	_	730
Forward Foreign Currency Contracts	_	50,200	_	50,200
Total	\$ 60,159,623	\$ 105,155,674	\$ 455,324	\$ 165,770,621

Liabilities	Level 1	Level 2	Level 3	Total	
Derivatives (b)					
Futures Contracts	\$ (516,587)	\$ _	\$ _	\$	(516,587)
Forward Foreign Currency Contracts	_	(3,603)	_		(3,603)
Total	\$ (516,587)	\$ (3,603)	\$ _	\$	(520,190)

During the period ended January 31, 2025, the amount of transfers between Level 2 and Level 3 was \$468,211. The investments were transferred from Level 2 to Level 3 due to the lack of observable market data due to a decrease in market activity. Transfers between price levels are recognized at the beginning of the reporting period.

- (a) See Consolidated Investment Portfolio for additional detailed categorizations.
- (b) Derivatives include unrealized appreciation (depreciation) on open futures contracts and forward foreign currency contracts.

OBTAIN AN OPEN-END FUND PROSPECTUS

To obtain a summary prospectus, if available, or prospectus, download one from fundsus.dws.com, talk to your financial representative or call (800) 728-3337. We advise you to carefully consider the product's objectives, risks, charges and expenses before investing. The summary prospectus and prospectus contain this and other important information about the investment product. Please read the prospectus carefully before you invest.

CLOSED-END FUNDS

Closed-end funds, unlike open-end funds, are not continuously offered. There is a one time public offering and once issued, shares of closed-end funds are sold in the open market through a stock exchange. Shares of closed-end funds frequently trade at a discount to net asset value. The price of the fund's shares is determined by a number of factors, several of which are beyond the control of the fund. Therefore, the fund cannot predict whether its shares will trade at, below or above net asset value.

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas Inc. and RREEF America L.L.C. which offer advisory services.

NO BANK GUARANTEE | NOT FDIC INSURED | MAY LOSE VALUE

DGMF-PH1 R-080548-3 (1/27)